Entity

Time filter

Source Type


Trademark
Astellas Pharmaceutical Co., Astellas Pharma Inc., Yamanouchi Pharma Technologies Inc. and Yamanouchi Pharmaceutical Co. | Date: 2003-10-07

Pharmaceutical Preparations that Dissolve in the Mouth for the Treatment of Disease or Health-related Conditions Involving Blood and Blood-forming Organs, the Cardiac Circulatory System, the Peripheral Vascular System, The Endocrine System, the Genitourinary System, the Immune System, Infectious and Parasitic Conditions, the Lower Digestive System, Mental Disorders, Metabolic Disorders, Multi-system and Ill-defined Conditions, Muskoskeletal Systems, and Connective Tissue, Neoplasms, the Nervous System, Nutritional Disorders, Pregnancy, the Respiratory System; Sensory Organ Conditions, Skin and Subcutaneous Conditions, and the Upper Digestive System.


Trademark
Astellas Pharmaceutical Co., Astellas Pharma Inc., Yamanouchi Pharma Technologies Inc. and Yamanouchi Pharmaceutical Co. | Date: 1998-02-10

pharmaceutical preparations that dissolve in the mouth for the treatment of disease or health related conditions involving blood and blood-forming organs, the cardiac circulatory system, the peripheral vascular circulatory system, the endocrine system, the genitourinary system, the immune system, infectious and parasitic conditions, the lower digestive system, mental disorders, metabolic disorders, multi-system and ill-defined conditions, muscloskeletal systems and connective tissue, neoplasms, the nervous system, nutritional disorders, pregnancy, the respiratory system, sensory organ conditions, skin and subcutaneous conditions, and the upper digestive system.


Trademark
Astellas Pharmaceutical Co., Astellas Pharma Inc., Yamanouchi Pharma Technologies Inc. and Yamanouchi Pharmaceutical Co. | Date: 2004-11-02

SWALLOW-FACILITATING FORMULATION SOLD AS AN INTEGRAL COMPONENT OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASE OR HEALTH-RELATED CONDITIONS INVOLVING BLOOD AND BLOOD-FORMING ORGANS, THE CARDIAC CIRCULATORY SYSTEMS, THE PERIPHERAL VASCULAR CIRCULATORY SYSTEM, THE ENDOCRINE SYSTEM, THE GENITOURINARY SYSTEM, THE IMMUNE SYSTEM, INFECTIOUS AND PARASITIC CONDITIONS, THE UPPER AND LOWER DIGESTIVE SYSTEM, MENTAL DISORDERS, METABOLIC DISORDERS, MULTI-SYSTEM AND ILL-DEFINED CONDITIONS, MUSCULOSKELETAL SYSTEMS AND CONNECTIVE TISSUE, NEOPLASMS, THE NERVOUS SYSTEM, NUTRITIONAL DISORDERS, PREGNANCY, THE RESPIRATORY SYSTEM, SENSORY ORGAN CONDITIONS, SKIN AND SUBCUTANEOUS CONDITIONS.


Trademark
Astellas Pharmaceutical Co., Astellas Pharma Inc., Yamanouchi Pharma Technologies Inc., Yamanouchi Pharmaceutical Co. and Shaklee Corp. | Date: 2002-02-26

Pharmaceutical Preparations for the Treatment of Disease or Health-Related Conditions Involving Blood and Blood-Forming Organs, the Cardiac Circulatory System, the Peripheral Vascular Circulatory System, The Endocrine System, the Genitourinary System, the Immune System, Infectious and Parasitic Conditions, the Lower Digestive System, Mental Disorders, Metabolic Disorders, Multi-System and Ill-Defined Conditions, Musculoskeletal Systems and Connective Tissue, Neoplasms, the Nervous System, Nutritional Disorders, Pregnancy, the Respiratory System, Sensory Organ Conditions, Skin and Subcutaneous Conditions, and the Upper Digestive System; and Nutritional Supplements.


Ikegai K.,Astellas Pharmaceutical Inc. | Imamura M.,Astellas Pharmaceutical Inc. | Suzuki T.,Astellas Pharmaceutical Inc. | Nakanishi K.,Astellas Pharmaceutical Inc. | And 11 more authors.
Bioorganic and Medicinal Chemistry | Year: 2013

Here, a series of C-glucosides with azulene rings in the aglycon moiety was synthesized and the inhibitory activities toward hSGLT1 and hSGLT2 were evaluated. Starting from the azulene derivative 7 which had relatively good SGLT2 inhibitory activity, compound 8a which has a 3-[(azulen-2-yl)methyl]phenyl group was identified as a lead compound for further optimization. Introduction of a phenolic hydroxyl group onto the central benzene ring afforded a potent and selective SGLT2 inhibitor 8e, which reduced blood glucose levels in a dose-dependent manner in rodent diabetic models. A mono choline salt of 8e (YM543) was selected as a clinical candidate for use in treating type 2 diabetes mellitus. © 2013 Elsevier Ltd. All rights reserved. Source

Discover hidden collaborations